## **RNTCP** Request Form for examination of biological specimen for TB

		(Requirea to		of TB, Drug su ent Informa		<u> </u>	and follow u	ıp)								
Patient name	_		<u> </u>			<u>n</u> rs):		Gender: □M □	TE FITC							
Patient name						-		Gender: □M □  Sputum	JF 1116							
or other cont				-		n collection	)	☐ Other								
Aadhaar no.				date (i	)D/M	/IM/YY)		(specify)								
					HIV Status: □Reactive □Non-Reactive □Unknown											
Patient addre				Key p	Key populations: □Contact of known TB Patient □Contact											
with landmar	/ <b>k</b>				of known DR TB Patient □Diabetes □Tobacco □Prison □Miner □Migrant □Refugee □ Urban slum □Health-care											
<b></b>				worker	ПС	Other(specify)										
Name and Ty	/pe of refer	ring facilit ne/DR-TB Ce	.y (PHI/DMC ntre/RBSK/P	ype of patient: ☐ Public sector ☐ Private sector												
Others, specify):	:				E	pisode ID: _										
Health Estab State:	ان <u>lishment</u>		(Y): istrict:		Tuberculosis Unit (TU):											
Reason for Te	coting		<u> </u>		i uberculosis offic (10)											
Reasonionio	Diagnosis and follow up of TB															
Diagnosis of T	TR (for pres	umntive TE		UVV	Follow up (Smear and culture)											
H/O anti TB R		•	•			T One a sign										
☐ TB symptor	matic			nant sympto	 om	Reason:		End IP □ En	d CP							
☐ Any abnorn		ay	ĺ		Ī	Post treatr	nent 🔲 (	6m □ 12m □	18m □							
<ul><li>□ Repeat Exa</li><li>□ Presumptiv</li></ul>		ļ	Duration:	:days	I	24m										
□ г тозитъ	CIVIIVI					<u> </u>										
L			nosis and	J follow up	Dr	ug-resistan										
Diagnosis of I	,					Follow up	•									
Presumptive	☐ At TB dia	New □ Pi	reviously tre	eated			Treatment follow up month: Type of case:									
MDR TB		· ·			I	☐ H mono/poly TB ☐ MDR/RR TB ☐ XDR TB										
·	•	p Sm+ve DS				Regimen Type:  ☐ All oral H mono/poly TB regimen										
	☐ Presum	ptive H mo	no/poly													
1		R TB at Diagi	nocie		1	☐ Shorter MDR TB regimen ☐ All oral longer regimen ☐ Any other regimen										
Presumptive		· ·			I											
XDR TB		of MDR/RR T	Ū		1		ition:									
1	☐ Recurren	nt case of se	cond line tr	eatment	Regimen composition: □ Lfx □ Mfx <sup>h</sup> □ Bdq □ Lzd □ Cfz □ Cs □ Z											
<u></u>								m   Km   Cm								
Test requeste																
								☐ CBNAAT [ ecify)								
				ignature):		•	•									
Contact Num				Email ID	):											
Results:																
				opy (□ ZN	1 🗆	l Florescent)		ID:								
1 ,	Lab Sr. No		sual	<u></u>			Result									
		+	arance	Negative	:	Scanty	1+	2+	3+							
Sample A Sample B	!		M B M B	<del></del>	+				+							
Date tested: Date Reported: Reported by: (Name and Signature)																

Nucleic Acid Amplification Test (NAAT) Lab serial Test ID:																							
Type of test																							
Sample			□A □B																				
M. Tuberc	ulos	is	☐ Detected ☐ Not Detected ☐ N/A																				
Rif Resista	cted					] No	t De	etect	ed			Ind	eterr	nina	te			I/A					
Test ☐ No Result ☐ In												l Err	or –	Erro	r Co	de_			_ (Plea	ase ar	range fo	or fresh	sample)
	Date tested: Date Reported: Reported by: (Name and Signature)																						
Laboratory Name: (Name and Signature)																							
							Cι	ıltu	re ([	] L	J [	J L(	C)				Test	ID:					
Lab Sr. No	ega	ative Positive						NTM (write spe							5)		С	Contamination					
			Date Reported: Reported by:														٦ C:						
Laboratory Name: (Name and Signature)															ure)								
			First line LPA						Lab serial T														
	ct ⊔		direct													etect	ed L						
Drug			Resistant detected							Final interpretation											Ken	nark	
Rifampicin (							ed □ No If yes or infe																
Isoniazid (Ka	,				Inferi				•	yes or inferred, H(h) should not be given													
Isoniazid (In	red	□ No	0	If yes or inferred, H(h) can be considered & Eto should not be given																			
Date Resu	lt:					Date	Re	por	ted:					R	epc	rte	d by:						
Laborato	ry N	lam	e: _																		nd Si	igna	ture)
□ Dina		1	1:	Se	cond	line	LPA	<u> </u>		l'	: 4	<u>L</u> ;	ab se	rial	N/T	D 414			t ID:				
Drug	CT 🗀				ant d				d □ Invalid □ MTB detected □MTB not detected  Final interpretation Remark														
										If yes or inferred, Lfx should not be given. M								Mfx	(h)		IVEII	iain	
Levofloxac	☐ Yes ☐ Inferred ☐ No						can be considered.																
Moxifloxaci	ın (h	)	☐ Yes ☐ No						If yes, Lfx & Mfx (h) should not be given														
Amikacin									If yes or inferred, Am should not be given														
Kanamycin		□ Ye	☐ Yes ☐ Inferred ☐ No						If yes or inferred, Km should not be given														
Capreomycin ☐ Yes ☐ Inferred ☐								0	If yes or inferred, Cm should not be giver								given						
Date Result: Date Reported: Reported by:																							
Laboratory	y Na	me	:									_						(Na	me	and	Sig	natu	re)
Drug Susceptibility Test (DST) results Test ID:																							
		<b>1</b> st	line drugs SLI						FQ						Test ID: Other								_
					<u> </u>							_	<u> </u>							<del> </del>			
Lab Sr.No	~	H (0.1)	H (0.4)	Z	ш	S	Ж	Cm	Am	Lfx	Mfx (0.5)	Mfx (1.0)	Mfx (2.0)	PAS	Lzd	Cfz	Bdq	DIM	Eto	Cs	ਹੋ	Azi	
											_	1	<del>  -</del>				+		<u> </u>				
Date Been	   <b>4</b> -	l	1	1		)ata	Par	200	tod:	1	1	1	1		\ \ \ \	+64	by:	1	1	1	1	1	1 1
Date Result: Date Reported: Reported by:   Laboratory Name: (Name and Signature)  R: Resistant; S: Susceptible; C: Contaminated; Not done																							
			-									D -	icar	00:			Ter	+ 10-					
Test (Plea	مو د	ner	if\/\·						er tes		UI I	<b>D</b> 0	iagn	USIS	•		res	נוט:					
															_								
Date repo	Result: Reported by: (Name and Signature)																						
Laborator	v Na	me																<b>/N</b>	Jam	o ar	N Si	anat	ura)

Date of specimen received: